Drug intelligence / Profile preview

JHG002

Development stage: Phase 1
Lead developer: Jaseng Medical Foundation
Modality: Peptides
Administration: Injection

Overview

JHG002 is a purified Hominis placenta extract developed by the Jaseng Medical Foundation for the treatment of chronic low back pain. It is administered via pharmacopuncture, a therapeutic technique in Korean medicine that combines acupuncture with the injection of herbal or biological extracts into specific acupuncture points. The extract is traditionally used to support vitality, alleviate chronic pain, and promote functional recovery. JHG002 is currently being investigated in multicenter randomized controlled trials to evaluate its clinical effectiveness and safety compared to conventional non-invasive treatments like transcutaneous electrical nerve stimulation (TENS).

Other names: Hominis placental pharmacopunctureHominis placenta extract

Beyond the preview

Go deeper on JHG002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JHG002.

Explore the full profile